MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study

Phil Ambery(Adaptimmune (United Kingdom)), Victoria E R Parker, Michael Stümvoll(University Hospital Leipzig), Maximilian Posch(Charité - Universitätsmedizin Berlin), Tim Heise(Profil Institute for Metabolic Research), Leona Plum-Moerschel(Profil Institute for Metabolic Research), Lan-Feng Tsai, Darren Robertson, Meena Jain, Marcella Petrone, Cristina M. Rondinone, Boaz Hirshberg, Lutz Jermutus

The Lancet

June 1, 2018

10.1016/s0140-6736(18)30726-8

Cited by 295

Abstract

Related Papers

Standards of Medical Care in Diabetes

David V. Power|Diabetes Care|2006|8.7k

Abdominal Visceral and Subcutaneous Adipose Tissue Compartments

Caroline S. Fox, Joseph M. Massaro, Udo Hoffmann et al.|Circulation|2007|2.9k

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

Juris J. Meier|Nature Reviews Endocrinology|2012|1.3k

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes

Melanie J. Davies, Richard M. Bergenstal, Bruce W. Bode et al.|JAMA|2015|1.1k

Beneficial health effects of modest weight loss.

D J Goldstein|PubMed|1992|920